An innovative approach to simultaneously attacking cancer cells and fibroblasts protecting against cancers using viruses is devised

Cancer cells utilize human healthy cells to protect fibroblasts and transport cancer cells. In a new study, we succeeded in destroying not only cancer cells but also fibroblasts protecting cancer cells by infecting cancer cells with the virus. In a similar study done in the past, this technique was said to be "innovative" as healthy cells were also shown to be attacked.

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells | Cancer Research
http://cancerres.aacrjournals.org/content/early/2018/11/15/0008-5472.CAN -18-1750

Modified virus used to kill cancer cells | University of Oxford
http://www.ox.ac.uk/news/2018-11-20-modified-virus-used-kill-cancer-cells

This research is based on the oncolytic adenovirus formulation "Enadenotucirev" developed by British biotechnology company PsiOxus . Enadenotucirev is already in the clinical trial stage of cancer treatment in the United States and Europe and is designed to infect virus only to cancer cells and leave healthy cells in the body.

Researchers have incorporated Genetic Instructions on Enadenotucirev "to produce a fusion protein called Bi-specific T-cell engager (BiTE) in infected cancer cells". BiTE is a protein that binds fibroblasts and T cells and is a trigger that causes T cells to attack fibroblasts.

Joshua Freedman of Oxford University, the 1st author of the paper said: "We hijacked the mechanism of the virus and made BiTE only with virus-infected cancer cells.BiTE is suppressed by cancer It is so powerful that it activates immune cells in the tumor and begins to attack fibroblasts. "

Kerry Fisher of the University of Oxford who also worked on the study said, "Even if most of the cancer cells in the tumor were killed, the fibroblasts protected the remaining cancer cells and helped them recover and prosper again There has never been a way to attack both cancer cells and fibroblasts that protect them at the same time without hurting the healthy part of the body. "" Fibroblasts are also killed while killing cancer cells Our new targeting technology is to reduce repression of the immune system in the tumor and start a standard immune process. "

by Hal Gatewood

Since Enadenotucirev is already at the stage of clinical trial, we will start a clinical trial in 2019, with this technology adding Enadenotucirev as well.

This study was conducted on samples of cancer cells collected with agreement of cancer patients. At the same time, experiments were also carried out on healthy human bone marrow samples, but T cells were said to have not been inappropriately activated or toxic.

The research was originally funded by the Medical Radiological Safety Management Center (MRC) and the Royal Cancer Research Foundation. Nathan Richardson of MRC says, "Immunotherapy is becoming an exciting new approach to cancer treatment, an innovative way to target both cancer cells and the surrounding protective organizations is now We will have good results for cancer patients who are tolerated. "

by rawpixel Follow Message

Michelle Lockley of Royal Cancer Research Foundation also said, "The method of using the immune system owned by the body to defeat cancer is a growing research field.The experiments on human tumor samples are successful It is a complex one The main challenge of immunotherapy is to predict how it works well in the patient's immune system and to understand what side-effects will occur. Clinical trials will confirm that this method can safely and effectively treat patients. "